|
|
|
|
|
|
|
SIZE:
|
|
|
|
GENERIC NAME:
|
|
|
|
MANUFACTURER:
|
|
|
|
UNIT:
|
|
|
|
ADMINISTRATION ROUTE:
|
|
|
|
FDA PREGNANCY GROUP:
|
|
C
|
|
INDICATIONS:
|
|
Embolism, arterial, prophylaxis |
|
Arrhythmia, atrial, with embolism |
|
Disseminated intravascular coagulation |
|
Embolism, arterial |
|
Embolism, pulmonary |
|
Embolism, pulmonary, prophylaxis |
|
Thrombosis, deep vein, prophylaxis |
|
Thrombosis, venous |
|
Thrombosis, venous, prophylaxis |
| |
|
|
SIDE EFFECTS:
|
|
Allergic reaction |
|
anaphylactoid reaction, possibly including anaphylactic shock |
|
chest pain |
|
frequent or persistent erection |
|
itching and burning feeling, especially on the plantar site of the feet |
|
pain, coldness, and blue color of skin of arms or legs |
|
peripheral neuropathy |
|
Bleeding from gums when brushing teeth |
|
heavy bleeding or oozing from cuts or wounds |
|
unexplained bruising or purplish areas on skin |
|
unexplained nosebleeds |
|
unusually heavy or unexpected menstrual bleeding |
|
Abdominal pain or swelling |
|
back pain or backaches |
|
blood in urine |
|
bloody or black, tarry stools |
|
constipation caused by hemorrhage-induced paralytic ileus or intestinal obstruction |
|
coughing up blood |
|
dizziness |
|
headaches, severe or continuing |
|
joint pain, stiffness, or swelling |
|
vomiting of blood or material that looks like coffee grounds |
|
Osteoporosis |
|
unusual hair loss |
|
Hematoma |
|
histamine-like reaction |
|
hives, localized |
|
irritation, pain, redness, or ulceration |
|
necrosis, cutaneous |
|
|
ABSOLUTE
CONTRAINDICATIONS :
|
|
|
|
RELATIVE
CONTRAINDICATIONS : |
|
Allergic reaction to heparin |
|
Allergy or asthma |
|
Any medical or dental procedure or condition in which the risk of bleeding or hemorrhage is present |
|
>> Anesthesia, regional or lumbar block |
|
>> Blood dyscrasias, hemorrhagic, especially thrombocytopenia or hemophilia; or other hemorrhagic tendency |
|
>> Childbirth, recent |
|
Diabetes, severe |
|
>> Endocarditis, subacute bacterial |
|
Gastrointestinal ulceration |
|
Intrauterine contraceptive device, use of |
|
>> Neurosurgery, recent or contemplated |
|
>> Ophthalmic surgery, recent or contemplated |
|
>> Pericarditis or pericardial effusion |
|
Radiation therapy, recent |
|
Renal function impairment, mild to moderate |
|
>> Renal function impairment, severe |
|
>> Spinal puncture, recent |
|
>> Surgery, major, or wounds resulting in large open surfaces |
|
>> Trauma, severe, especially to the central nervous system |
|
Tuberculosis, active |
|
>> Ulceration or other lesions of the gastrointestinal, respiratory, or urinary tract, active |
|
>> Vasculitis, severe |
|
Hepatic function impairment, mild to moderate |
|
>> Hepatic function impairment, severe |
|
Hypertension, mild to moderate |
|
|
ADULT DOSE:
|
|
Full-dose (therapeutic) regimen-Subcutaneous, deep (intrafat), 10,000 to 20,000 USP Units initially, then 8000 to 10,000 USP Units every eight hours or 15,000 to 20,000 USP Units every twelve hours, or as determined by coagulation test results. This dosage schedule is usually preceded by a loading dose of 5000 USP Units administered by intravenous injection.
Intravenous, 10,000 USP Units initially, then 5000 to 10,000 USP Units every four to six hours or 100 USP Units per kg of body weight every four hours, or as determined by coagulation test results. The dose may be administered undiluted or diluted with 50 to 100 mL of 0.9% sodium chloride injection.
Intravenous infusion, 20,000 to 40,000 USP Units in 1000 mL of 0.9% sodium chloride injection, administered over a twenty-four-hour period. This dosage schedule is usually preceded by a loading dose of 35 to 70 USP Units per kg of body weight or 5000 USP Units, administered by intravenous injection. The infusion is often administered at a rate of l000 USP Units per hour; however, dosage must be adjusted as determined by coagulation test results.
Note: Recommendations for specific indications include:
Heart and blood vessel surgery-Intravenous, initially not less than l50 USP Units per kg of body weight. Doses of 300 USP Units per kg of body weight are often used for procedures expected to last less than 60 minutes and doses of 400 USP units per kg of body weight are often used for procedures expected to last longer than 60 minutes. It is recommended that subsequent doses be based on coagulation test results.
Disseminated intravascular coagulation-Intravenous, 50 to 100 USP Units per kg of body weight every four hours, administered by continuous infusion or as a single injection. The medication should be discontinued if no improvement occurs within 4 to 8 hours.
Adjusted-dose regimen-Subcutaneous, deep (intrafat), an established dose to be injected every twelve hours. The required dose is determined by adjusting heparin dosage until the midinterval (six hours after an injection) activated partial thromboplastin time (APTT) is maintained at one and one-half times the control value.
Low-dose (prophylactic) regimen-Subcutaneous, deep (intrafat), 5000 USP Units two hours before surgery and every eight to twelve hours thereafter for seven days or until the patient is fully ambulatory, whichever is longer. |
|
MAXIMUM ADULT DOSE:
|
|
|
|
PEDIATRIC DOSE:
|
|
Intravenous, 50 USP Units per kg of body weight initially, then 50 to 100 USP Units per kg of body weight every four hours, or as determined by coagulation test results.
Intravenous infusion, 50 USP Units per kg of body weight as a loading dose initially, then 100 USP Units per kg of body weight added and absorbed every four hours or 20,000 USP Units per square meter of body surface every twenty-four hours, or as determined by coagulation test results.
Note: Recommendations for specific indications include:
Disseminated intravascular coagulation-Intravenous, 25 to 50 USP Units per kg of body weight every four hours, administered by continuous infusion or as a single injection. The medication should be discontinued if no improvement occurs within 4 to 8 hours.
Heart and blood vessel surgery-Intravenous, initially not less than l50 USP Units per kg of body weight. Doses of 300 USP Units per kg of body weight are often used for procedures expected to last less than 60 minutes. It is recommended that subsequent doses be based on coagulation test results. |
|
MAXIMUM PEDIATRIC
DOSE:
|
|
|
|
ELDERLY DOSE:
|
|
|
|
|
|
|
|